Allergan, Inc. (NYSE:AGN)

generic drugs

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

As we trudge through the dog days of August toward the traditional end-of-summer market slowdown, many of the firms we cover on Wall Street are making changes to their top ...
Read Full Story »
health care

What to Expect From Allergan Earnings

Allergan PLC (NYSE: AGN) is scheduled to report its second-quarter financial results Thursday before the markets open. The consensus estimates from Thomson Reuters call for $4.38 in earnings per share ...
Read Full Story »
buy sell

UBS Makes August Changes to Equity Focus List Portfolio

With the dog days of summer upon us, and the market starting to really slow down, some Wall Street firms are making the last changes for the third quarter recommendations ...
Read Full Story »
Biotechnology word cloud

3 Potential Huge Takeover Targets in Biotech

Usually when you think of a biotech takeover, it is a large cap biotech or pharmaceutical company that dives in and buys a small market cap stock with solid clinical ...
Read Full Story »
payoff

Teva Proves Its Decade-Hold Status With Massive Funding

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has ...
Read Full Story »
Merger

What Allergan Is Looking to Add With Kythera

The health care sector has been red hot over the past year, feeding numerous possibilities for mergers and acquisitions. Allergan PLC (NYSE: AGN) decided to strike while the iron was ...
Read Full Story »
NYSE-flag

American Airlines Replaces Allergan in S&P 500

American Airlines Group Inc. (NASDAQ: AAL) will be the newest addition to the S&P 500, taking the place of Allergan Inc. (NYSE: AGN). The change will occur after the close ...
Read Full Story »
generic drugs

As Valeant Ups Salix Buyout, Will Endo Come Back?

Monday morning, Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Valeant Pharmaceuticals International Inc. (NYSE: VRX) both announced that they had entered into an agreement on their plan to merge based on ...
Read Full Story »
95992888

9 Big Stocks That Doubled in 2014

The S&P 500 index has gained just over 12% in the past 52-weeks, a good effort, but far below the 32% return in 2013 and not quite up there with ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: AK Steel, Alcoa, EA, Intel, IBM, Sony, Tyco, Wells Fargo and More

Stocks were looking for direction on Tuesday morning. Investors keep proving each day that they are willing to buy stocks that are discounted or that are overlooked. 24/7 Wall St. ...
Read Full Story »
Botox injection

Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out

Botox maker Allergan Inc. (NYSE: AGN), which has fended off offers up to about $173 per share from Valeant Pharmaceuticals International Inc. (NYSE: VRX), announced Monday morning that it has ...
Read Full Story »
irrigation

What Does ValueAct See in Taking an Activist Role in Fertilizers?

Hedge fund ValueAct Capital Management on Friday filed a Form 13-D with the U.S. Securities and Exchange Commission (SEC) disclosing the acquisition of 8.19 million shares of Canada-based fertilizer maker ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Apple, Gap, Intel, J.C. Penney, Kinder Morgan and More

Stocks were selling off marginally on Thursday morning after the Fed minutes prompted a rally on Wednesday. Yet again, investors proved how willing they are to buy overlooked or oversold ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Boeing, eBay, Hecla Mining, Janus Capital, Orbitz, Ford and More

Stocks were soft on Wednesday after weak data in Europe and after an Ebola case was confirmed in the United States. Still, investors have shown over and over that they ...
Read Full Story »
biotech

3 Likely Biotech Buyout Candidates

The pharmaceutical business is a difficult one, because patent expiration and competition are always omnipresent factors. Obviously major companies like to keep large research and development projects moving at full ...
Read Full Story »